

## 170.315(b)(3) – Electronic Prescribing

### Real World Testing 2021

#### GENERAL INFORMATION

Plan Report ID Number: 2021v1\_B3

Developer Name: Systemedx, Inc.

Product Name(s): Systemedx Clinical Navigator

Version Number(s): 2022.12

Certified Health IT Product List (CHPL) Product Number(s): 15.04.04.2857.Syst.22.01.1.221215

Developer Real World Testing Plan and Result Page URL: <https://www.systemedx.com/mipssolutions.html>

#### WITHDRAWN PRODUCTS

*If a developer withdrew any products within the past year that were previously included in their Real World Testing plan, please provide the following information.*

<b>Product Name(s):</b>	<b>Systemedx Clinical Navigator</b>
<b>Version Number(s):</b>	2019.10
<b>CHPL Product Number(s):</b>	15.04.04.2857.Syst.19.01.1.191208
<b>Date(s) Withdrawn:</b>	12/31/2022
<b>Inclusion of Data in Results Report:</b> [Provide a statement as to whether any data was captured on the withdrawn products. If so, this data should be identified in the results report.]	Most data represented in this report period was captured utilizing this withdrawn version as the new version did not replace it prior to year end.

## 170.315(b)(3) – Electronic Prescribing

Real World Testing 2021

### SUMMARY OF TESTING METHODS AND KEY FINDINGS

The data used for reporting this comes from data tracked across 16 clinics. Of the clinic's, five are non-specialty.

Across all settings polled for the year 2022, 99.6% of all new generated prescriptions transmitted successfully to the pharmacy without an error. The quarter with the most completed prescriptions was the 1st quarter of the year (January-March) and the quarter with the highest completion percentage was the second quarter of April-June.

### STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

*Both required and voluntary standards updates must be addressed in the Real World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made.*

*Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).*

☐ Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below.

☒ No, none of my products include these voluntary standards.

#### Care Setting(s)

*The expectation is that a developer's Real World Testing is conducted within each type of clinical setting in which their certified health IT is marketed. Health IT developers are not required to test their certified health IT in every setting in which it is marketed for use.*

*List each care setting that was tested.*

Ambulatory Internal/Family Medicine
Ambulatory Orthopedics
Ambulatory Allergy Clinics
Other Specialties (including Rheumatology, surgery, neurology)

#### Metrics and Outcomes

##### DESCRIPTION OF MEASUREMENT/METRIC

The percentage of patients that had successful electronic prescriptions successfully transmit as indicated by the status messages returned from partner Surescripts.

##### ASSOCIATED CERTIFICATION CRITERIA

## 170.315(b)(3) – Electronic Prescribing

Real World Testing 2021

### 170.315(b)(3) – Electronic Prescribing

---

#### OUTCOMES

The expected outcome for this measure was that there will be a greater than 95% success rate of prescription transmission.

The resulting data proved this assumption to be true with a greater than 99% e-script transmission rate.

---

#### RELIED UPON SOFTWARE

Successful transmission of electronic prescriptions relies upon interfacing with Surescripts to deliver the messages and return response messages to the certified ehr product from the pharmacies.

#### KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
First Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	Jan - March
Second Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	March - June
Third Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	July - Sept
Fourth Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	Oct - Dec